Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling

BACKGROUND: Docetaxel plays an indispensable role in the management of advanced prostate cancer (PCa). However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Muniyan, Sakthivel, Rachagani, Satyanarayana, Parte, Seema, Halder, Sushanta, Seshacharyulu, Parthasarathy, Kshirsagar, Prakash, Siddiqui, Jawed A., Vengoji, Raghupathy, Rauth, Sanchita, Islam, Ridwan, Mallya, Kavita, Datta, Kaustubh, Xi, Lei, Das, Anindita, Teply, Benjamin A., Kukreja, Rakesh C., Batra, Surinder K.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642013/
https://ncbi.nlm.nih.gov/pubmed/32847934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1569
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים